Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
The embodiments include methods of ameliorating or preventing the worsening or progression and/or ameliorating or preventing the worsening or lack of improvement of symptoms of BPH in mammals, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.
1. A method of ameliorating or preventing the worsening or progression of symptoms of benign prostatic hyperplasia (BPH) in one or more mammals having BPH and showing no increase in International Prostate Symptom Score (IPSS) over time, comprising administering to the one or more mammals a therapeutically effective amount of a peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu, and when administered to more than one mammal, reducing the percentage of mammals exhibiting worsening or the progression of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) by more than 10%, when compared to administering a control.
2. The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of the peptide as claimed in claim 1 and a carrier.
3. The method of claim 1 , wherein the peptide is administered more than once.
4. The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of the peptide as claimed in claim 1 , having at least one and up to 25 additional amino acids flanking either the N-terminus or C-terminus of SEQ ID NO. 66.
5. The method of claim 1 , wherein the peptide is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intraprostatically, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally.
6. The method of claim 1 , wherein reducing the percentage of mammals exhibiting worsening or the progression of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) is from about 20% to about 65%, when compared to mammals receiving a control.
7. The method of claim 6 , wherein reducing the percentage of mammals exhibiting worsening or the progression of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) is from about 30% to about 60%, when compared to mammals receiving a control.
8. The method of claim 6 , wherein reducing the percentage of mammals exhibiting worsening or the progression of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) is from about 35% to about 60%, when compared to mammals receiving a control.
9. The method of claim 1 , further comprising administering to the mammal an additional therapeutic agent selected from the group consisting of alfuzosin, tamsulosin, dutasteride, tadalafil, terazosin, finasteride, doxazosin, combinations of finasteride and doxazosin, and mixtures thereof.
10. The method of claim 1 , the method further ameliorating or preventing the lack of improvement of symptoms of benign prostatic hyperplasia (BPH) in the mammal.
11. The method of claim 10 , wherein the method comprises administration of a therapeutically effective amount of the peptide as claimed in claim 1 and a carrier.
12. The method of claim 10 , wherein the peptide is administered more than once.
13. The method of claim 10 , wherein the method comprises administration of a therapeutically effective amount of the peptide as claimed in claim 1 , having at least one and up to 25 additional amino acids flanking either the N-terminus or C-terminus of SEQ ID NO. 66.
14. The method of claim 10 , wherein the peptide is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intraprostatically, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally.
15. The method of claim 10 , wherein ameliorating or preventing the lack of improvement of symptoms of BPH comprises, when administered to more than one mammal, reducing the percentage of mammals exhibiting worsening or the lack of improvement of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) by from about 10% to about 80%, when compared to mammals receiving a control.
16. The method of claim 15 , comprising reducing the percentage of mammals exhibiting worsening or the lack of improvement of symptoms of BPH, as measured by the International Prostate Symptom Score (IPSS) by from about 20% to about 75%, when compared to mammals receiving a control.
17. The method of claim 15 , comprising reducing the percentage of mammals exhibiting worsening or a lack of improvement of symptoms of BPH, as measured by the International Prostate Symptom (IPSS) by from about 25% to about 70%, when compared to mammals receiving a control.
18. The method of claim 10 , further comprising administering to the mammal an additional therapeutic agent selected from the group consisting of alfuzosin, tamsulosin, dutasteride, tadalafil, terazosin, finasteride, doxazosin, combinations of finasteride and doxazosin, and mixtures thereof.